CDEK
← All drugs Report issue

namilumab

mAbexperimental

Namilumab is a human monoclonal antibody that targets granulocyte macrophage-colony stimulating factor (GM-CSF)/colony stimulating factor 2 (CSF2) and is currently being researched for application in rheumatoid arthritis (RA) and psoriatic arthritis. Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis and rheumatoid arthritis. — Wikipedia

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2011 (NCT01317797)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • mt203
  • mt203
  • mt-203
  • namilumab
  • namilumab
  • namilumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05351554Phase 2Jun 30, 2022Kinevant Sciences GmbH
NCT05314517Phase 2Apr 30, 2022Kinevant Sciences GmbH
NCT03622658Phase 2Aug 8, 2018Innovate UK, IQVIA, Izana Bioscience Ltd.
NCT02393378Phase 2Apr 1, 2015Takeda
NCT02379091Phase 2Feb 1, 2015Takeda
NCT02354599Phase 1Nov 1, 2014Takeda
NCT02129777Phase 2Jun 1, 2014Takeda
NCT01317797Phase 1Mar 1, 2011Takeda
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TakedaFor profit5522011
Kinevant Sciences GmbHFor profit2212022
Innovate UKGovernment1012018
IQVIAFor profit1012018
Izana Bioscience Ltd.For profit1112018
5 organizations
Page 1 / 1